{"id":"mycophenolate-mofetil-standard-dose","safety":{"commonSideEffects":[{"rate":"19-45","effect":"Diarrhea"},{"rate":"13-45","effect":"Leukopenia"},{"rate":"20-27","effect":"Infection"},{"rate":"10-26","effect":"Anemia"},{"rate":"6-13","effect":"Thrombocytopenia"},{"rate":"10-19","effect":"Nausea"},{"rate":"9-16","effect":"Vomiting"},{"rate":"7-19","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1456","moleculeType":"Small molecule","molecularWeight":"433.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant isoform in lymphocytes. This blocks the de novo pathway of guanosine nucleotide synthesis, depleting guanosine nucleotides required for lymphocyte DNA synthesis and proliferation. The selective effect on lymphocytes makes it useful as an immunosuppressant with relatively sparing effects on other cell types.","oneSentence":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:43.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal transplant recipients"},{"name":"Prevention of organ rejection in cardiac transplant recipients"},{"name":"Prevention of organ rejection in hepatic transplant recipients"},{"name":"Active lupus nephritis (in combination with corticosteroids)"}]},"trialDetails":[{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":"Allogeneic Stem Cell Transplant Recipient","enrollment":209},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04883619","phase":"PHASE2","title":"A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-15","conditions":"Lupus Nephritis","enrollment":""},{"nctId":"NCT07359859","phase":"PHASE2","title":"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-20","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT05962788","phase":"PHASE3","title":"Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis","status":"TERMINATED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2024-03-28","conditions":"Adolescent Lupus Nephritis, Pediatric Lupus Nephritis","enrollment":4},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT04187105","phase":"PHASE2","title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-01-27","conditions":"Acute Leukemia, MDS","enrollment":27},{"nctId":"NCT05236036","phase":"PHASE1","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-08","conditions":"Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype","enrollment":60},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT02782546","phase":"PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT06799195","phase":"PHASE2","title":"Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-06-23","conditions":"Hematological Malignancies, Graft-versus-Host Disease (GVHD)","enrollment":126},{"nctId":"NCT04477629","phase":"PHASE2","title":"Belatacept in De Novo Heart Transplantation","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":"Heart Transplantation","enrollment":12},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT01903798","phase":"PHASE2","title":"A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Southern California Institute for Research and Education","startDate":"2014-12","conditions":"Alcoholic Hepatitis","enrollment":4},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT01350245","phase":"PHASE2","title":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia","enrollment":28},{"nctId":"NCT03781414","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-10-07","conditions":"Liver Transplant Rejection","enrollment":129},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT04376827","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Lupus Nephritis","enrollment":33},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":"COVID-19, Immunosuppression, Vaccine Response Impaired","enrollment":50},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT06297096","phase":"PHASE3","title":"Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-01","conditions":"Systemic Sclerosis, Interstitial Lung Disease","enrollment":86},{"nctId":"NCT05149768","phase":"PHASE2","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-02-14","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT06288932","phase":"PHASE3","title":"Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.","status":"COMPLETED","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2023-08-18","conditions":"Immune Thrombocytopenia Purpura","enrollment":118},{"nctId":"NCT06646497","phase":"PHASE2","title":"Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-01","conditions":"Aplastic Anemia","enrollment":52},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT04225988","phase":"PHASE4","title":"Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-01-09","conditions":"Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03605654","phase":"PHASE2, PHASE3","title":"Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants","status":"WITHDRAWN","sponsor":"Medeor Therapeutics, Inc.","startDate":"2024-12","conditions":"Kidney Transplant Rejection","enrollment":""},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06068179","phase":"PHASE2, PHASE3","title":"Graves' Disease Remission Study: MycoMeth Combo","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-10-16","conditions":"Graves' Disease","enrollment":205},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""},{"nctId":"NCT03734601","phase":"PHASE2","title":"Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-11-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder","enrollment":22},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT03198689","phase":"PHASE2","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-07","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT05101447","phase":"PHASE2","title":"Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis","status":"WITHDRAWN","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07","conditions":"Lupus Nephritis","enrollment":""},{"nctId":"NCT04927390","phase":"PHASE2","title":"Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-12-08","conditions":"Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis","enrollment":120},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT05073822","phase":"PHASE1, PHASE2","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2023-02-20","conditions":"Renal Transplant Rejection, Renal Transplant Infection","enrollment":""},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT04067180","phase":"NA","title":"Randomized Clinical Study Assessing Haplo vs. URD in AML","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2019-11-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT04903054","phase":"PHASE2","title":"Selective CD28 Blockade in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-01-10","conditions":"Kidney Transplantation, Renal Transplant Recipients","enrollment":""},{"nctId":"NCT03995901","phase":"PHASE3","title":"A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation","status":"TERMINATED","sponsor":"Talaris Therapeutics Inc.","startDate":"2019-10-25","conditions":"Transplanted Organ Rejection","enrollment":15},{"nctId":"NCT03917797","phase":"PHASE2","title":"Mesenchymal Stromal Cells (MSC´s) in Renal Lupus","status":"UNKNOWN","sponsor":"Universidad de los Andes, Chile","startDate":"2019-04-02","conditions":"Lupus Erythematosus, Systemic, Lupus Glomerulonephritis","enrollment":39},{"nctId":"NCT05061303","phase":"","title":"Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney","status":"UNKNOWN","sponsor":"Poznan University of Medical Sciences","startDate":"2021-10-17","conditions":"Kidney Rejection Transplant","enrollment":24},{"nctId":"NCT03388008","phase":"PHASE2","title":"Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-17","conditions":"Lung Transplant Rejection, Antibody-mediated Rejection","enrollment":27},{"nctId":"NCT02123108","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":"Liver Transplantation","enrollment":59},{"nctId":"NCT01682226","phase":"PHASE2","title":"Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-09-05","conditions":"Leukemia, Myelodysplastic Syndrome, Lymphoma","enrollment":84},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT01085097","phase":"PHASE2","title":"A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-09-01","conditions":"Lupus Nephritis","enrollment":46},{"nctId":"NCT05207358","phase":"PHASE4","title":"Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"Institutul Clinic Fundeni","startDate":"2022-03-02","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT02266888","phase":"PHASE2","title":"B Cell Induction in Pediatric Lung Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-22","conditions":"Lung Transplant","enrollment":45},{"nctId":"NCT02217410","phase":"PHASE1, PHASE2","title":"CCFZ533X2201 - PoC Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-05","conditions":"Kidney Transplantation","enrollment":59},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT04670926","phase":"NA","title":"Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test","status":"UNKNOWN","sponsor":"Transplant Genomics, Inc.","startDate":"2021-06-03","conditions":"Kidney Transplant Rejection, Immunosuppression","enrollment":75},{"nctId":"NCT01690520","phase":"PHASE2","title":"Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Nohla Therapeutics, Inc.","startDate":"2012-12-11","conditions":"Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission","enrollment":163},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00303719","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Kidney Cancer, Leukemia, Lymphoma","enrollment":342},{"nctId":"NCT00656266","phase":"PHASE4","title":"Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2004-11","conditions":"End-stage Liver Disease, Renal Insufficiency, Renal Failure","enrollment":13},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT02532777","phase":"PHASE2","title":"The Research of Standard Diagnosis and Treatment for HSPN in Children","status":"UNKNOWN","sponsor":"Nanjing Children's Hospital","startDate":"2015-08","conditions":"Henoch-Schoenlein Purpura Nephritis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CellCept"],"phase":"marketed","status":"active","brandName":"Mycophenolate mofetil, Standard dose","genericName":"Mycophenolate mofetil, Standard dose","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses. Used for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Autoimmune hemolytic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}